If this message is not displayed correctly, click here.

NDT-Edu@ENP Logo



Facebook Twitter LinkedIn

An official publication of


NDT-Educational@ENP Newsletter

Issue 2 - March 2019

EDITOR IN CHIEF: Davide Bolignano

EDITORIAL BOARD: click here for the complete list

NEWSLETTER DESIGN: Francesca Trebelli

Summary Reports from 55th ERA-EDTA Congress

The conundrum of treating gout in patients with CKD

presented by Jakub Závada


Gout is the most common inflammatory arthritis in the general population of the Western world, with an estimated prevalence ranging from 1.4%, in the UK and Germany, to 3.9% in the USA. However, in patients with chronic kidney disease (CKD), the prevalence is much higher, reaching 24% in those with CKD stages 3-4 in Germany, and nearly 30% in CKD stage 4 patients in the USA. As many as 31% of these patients are not treated at all, while nearly half of them (47%) are undertreated. Furthermore, patients with gout have much higher risk of having CKD.

Congress Presentation

This Congress talk has been presented by Jakub Zàvada during the 55th ERA-EDTA Congress in Copenhagen, Denmark.


New paradigms of the kidney – Vascular-bone axis in CKD

Presented by Klaus Olgaard


There has been no significant progress in the therapeutic management of chronic kidney disease (CKD)-mineral bone disorders (MBD) since the introduction of KDIGO CKD-MBD Guidelines in 2009, hence, an urgent need exists to better understand the pathophysiology of this condition. The new paradigm on the parathyroid-kidney–vascular-bone axis has revealed that CKD-MBD consists of a fascinating number of complex disturbances in the tissue cross-talk between these different organs in uraemia.

   Congress Presentation

This Congress talk has been presented by Klaus Olgaard during the 55th ERA-EDTA Congress in Copenhagen, Denmark.



Read this selection of articles about the two summary report fields.


ERA-EDTA Dialogues


A puzzling case for the transplantologist

by Ana Carina Ferreira

Therapeutic approach in multi-resistant FSGS: your opinion matters!

by Francesco Pesce


Is SGLT-2 inhibition being the dawn of a new era in preventing CKD progression in nondiabetic patients?

by Evangelia Ntounousi

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the EU General Data Protection Regulation (2016/679).